NYSE:ETWO
NYSE:ETWOSoftware

Will Improved Q1 Results and 2026 Guidance Change E2open’s (ETWO) Narrative?

E2open Parent Holdings, Inc. recently reported its first quarter 2025 results, showing revenue of US$152.61 million and a significant reduction in net loss to US$14.13 million compared to the prior year. Alongside improved financial performance, the company affirmed its full-year 2026 revenue guidance, providing stakeholders with greater visibility and confidence in its operational outlook. We'll explore how the company's continuation of annual guidance, despite current subscription revenue...
NYSE:RES
NYSE:RESEnergy Services

Why RPC (RES) Is Down 7.4% After Gary Kolstad Joins Board and What's Next

On July 14, 2025, RPC, Inc. announced that Gary Kolstad, an experienced oilfield services executive with a background in petroleum engineering, was appointed to the company’s Board of Directors. Kolstad’s combination of senior leadership experience and technical expertise suggests an added depth to RPC’s board as it focuses on operational and technological expansion. We’ll explore how Kolstad’s board appointment could influence RPC’s approach to industry challenges and its current investment...
NYSE:GEL
NYSE:GELOil and Gas

Should GEL's Newly Announced Quarterly Distributions Require Action From Genesis Energy (GEL) Investors?

Genesis Energy, L.P. has announced that its Board of Directors declared quarterly cash distributions for both common and preferred unit holders, scheduled for payment on August 14, 2025, to those of record as of July 31, 2025. This reaffirmation of distributions highlights Genesis Energy’s continued emphasis on shareholder returns and signals management’s confidence in the company’s current financial positioning. We’ll examine how this commitment to regular distributions could influence...
NasdaqGM:APGE
NasdaqGM:APGEBiotechs

Did Positive Phase 2 APG777 Results Just Shift Apogee Therapeutics' (APGE) Investment Narrative?

Earlier this month, Apogee Therapeutics announced positive 16-week results from Part A of its Phase 2 APEX trial evaluating APG777 in adults with moderate-to-severe atopic dermatitis, with the therapy meeting its primary efficacy endpoint and showing rapid itch relief and robust lesion reduction compared to placebo. Importantly, efficacy results for APG777 compared favorably across endpoints with existing standard of care biologics, while also maintaining a favorable safety profile and a low...